| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 368 | 14.258 | 14.496 | 74.279 | 87.950 |
| Total Income - EUR | - | - | - | - | - | 421 | 14.264 | 14.676 | 74.294 | 88.243 |
| Total Expenses - EUR | - | - | - | - | - | 1.503 | 7.674 | 15.160 | 54.944 | 43.763 |
| Gross Profit/Loss - EUR | - | - | - | - | - | -1.082 | 6.590 | -484 | 19.350 | 44.480 |
| Net Profit/Loss - EUR | - | - | - | - | - | -1.097 | 5.873 | -1.152 | 16.410 | 41.629 |
| Employees | - | - | - | - | - | 0 | 0 | 0 | 1 | 1 |
Check the financial reports for the company - Pharmaexcell S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 0 | 11.240 | 9.824 | 11.345 | 6.861 |
| Current Assets | - | - | - | - | - | 11.852 | 30.226 | 36.783 | 65.365 | 131.418 |
| Inventories | - | - | - | - | - | 3.012 | 9.222 | 5.449 | 8.426 | 42.884 |
| Receivables | - | - | - | - | - | 4 | 12.356 | 12.515 | 31.572 | 41.931 |
| Cash | - | - | - | - | - | 8.836 | 8.648 | 18.819 | 25.367 | 46.603 |
| Shareholders Funds | - | - | - | - | - | -1.113 | 4.785 | 3.648 | 20.047 | 61.563 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 12.965 | 36.682 | 42.959 | 56.663 | 76.716 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4727 - 4727" | |||||||||
| CAEN Financial Year |
4791
|
|||||||||
Comments - Pharmaexcell S.r.l.